Leidos is investing $10 million over five years to develop disease detection and management tools powered by artificial intelligence, in partnership with the University of Pittsburgh’s Computational Pathology and AI Center of Excellence, or CPACE.
The collaboration will initially focus on AI-enabled tools that can accelerate the detection of heart disease and cancer and diagnostic turnaround times and enable more effective care management, Leidos said Friday.
According to Leidos CEO Tom Bell, a two-time Wash100 awardee, the investment aims to speed up the treatment of various diseases affecting millions of people annually. “These efforts will also focus on developing future health care specialists, and expanding the care that’s available to underserved communities, including our veterans,” he added.
What Will the Project Entail?
As part of the agreement, Leidos and the University of Pittsburgh will jointly explore new imaging methods and advanced scanning technologies to analyze tissue samples and improved techniques for analyzing medical images. Both parties will also work on comprehensive educational programs, including industry-focused best practices, annual symposiums and hands-on internship opportunities to prepare the next generation of health care and AI innovators.
Leidos-University of Pittsburgh Collaboration Goals
Key objectives of the five-year partnership include establishing CPACE’s Digital Pathology Research Center as a world-class research hub, enabling Leidos to develop digital healthcare solutions designed to support digital health and diagnostics and accelerating the deployment of AI-powered digital pathology solutions with the goal of making the company a leader in the commercialization of innovative healthcare technologies.
